Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned a consensus recommendation of “Moderate Buy” from the twenty-eight brokerages that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $477.9604.

A number of brokerages have recently issued reports on ALNY. Barclays initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective for the company. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Leerink Partners dropped their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. Finally, Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease; the deal includes upfront cash and research funding plus up to $1.13 billion in milestone payments, expanding Alnylam’s RNAi pipeline into a large disease area. Read More.
• Positive Sentiment: Coverage notes a reimbursement win and reported trial progress for Alnylam’s programs — improving near‑term commercial visibility for approved RNAi medicines and supporting revenue upside against current valuation. Read More.
• Positive Sentiment: Industry backdrop remains supportive: market reports project strong growth for orphan drugs, which underpins long‑term demand for Alnylam’s rare‑disease franchises. Read More.
• Neutral Sentiment: Short‑interest figures in recent reports show zero shares and a 0.0 days‑to‑cover — this appears to be a reporting glitch and is unlikely to represent a real change in short positioning.
• Neutral Sentiment: Analyst coverage remains mixed to favorable with a consensus “Moderate Buy” and a wide range of price targets; useful context for longer‑term expectations but not an immediate driver.
• Negative Sentiment: Significant clustered insider selling: CEO Yvonne Greenstreet reported selling ~6,799 shares (~$2.23M) and multiple EVPs sold 1.6k–2.2k shares each across March 2–3. These concurrent executive sales (disclosed in SEC filings and insider summaries) can create short‑term negative sentiment and add selling pressure despite insiders retaining large holdings. Read More. Read More.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,799 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer directly owned 98,628 shares in the company, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 53,923 shares of company stock worth $18,072,087. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $25,000. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $27,000. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Finally, Golden State Wealth Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $320.51 on Friday. The company has a market cap of $42.51 billion, a P/E ratio of 187.43 and a beta of 0.36. The firm’s fifty day moving average price is $353.84 and its two-hundred day moving average price is $415.74. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the business posted ($0.65) EPS. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.